Draft Programme

09:00-17:00  Registration set up, exhibition, posters
14:00-17:30 Workshops - TBC

1. New approaches to diagnosis and treatment

2. Gonococcal vaccines 


3. Applications of omics 

18:00-20:30 Welcome Reception (Lagoon Beach Hotel)
07:00 Registration
09:00-09:15 Introduction/Welcome address (Anne von Gottberg, South Africa)
09:15-10:50 Meningitis in Africa
Chairs: TBC
09:15-09:45 Plenary: Brenda Kwambana-Adams (UK)
09:45-10:00 R. Mikhari (South Africa). Estimated coverage of MenB vaccine target protein types among serogroup B invasive meningococcal disease isolates in South Africa, 2016-2020 (abstract no. 296)
10.00:10.15 M. Paye (USA). Reinforcing laboratory diagnostic capacity for bacterial meningitis surveillance in the African Meningitis Belt (abstract no. 86)
10:15-10:30 A. Sadji (Togo). The epidemiology of bacterial meningitis in four northern regions of Togo, 2016-2019 (abstract no. 137)
10:30-10:40 G. Olanipekun (Nigeria). Etiologic agents of non-epidemic meningitis among pediatric patients in Nigeria: comparison of blood cultures with culture and PCR testing of CSF (abstract no. 247)
10:40-10:50 R. Charles-Amaza (Nigeria). Laboratory-based surveillance of Neisseria meningitidis in a cerebrospinal meningitis outbreak, Nigeria, 2017-2022 (abstract no. 337)
10:50-11:30 Coffee break
11:30-12:50 Host Defence and Immune Responses
Chairs: TBC
11:30-11:45 W. Song (USA). Neisseria gonorrhoeae infection modulates the local immune environment in the human cervix (abstract no. 82)
11:45-12:00 J. Laver (UK). Human nasal infection with chromosomally transformed Neisseria lactamica induces heterologous antigen-specific immunity (abstract no. 143)
12:00-12:15 R. Hardison (USA). Neisseria meningitidis urethritis clade (US_NmUC) acts as a ‘chimeric pathogen’ to adapt to the urethral environment (abstract no. 98)
12:15-12:30 N. Weyand (USA). Co-culture serum bactericidal assay: an assay for investigating the contributions of membrane-associated or soluble complement inhibitors to immune invasion by N. gonorrhoeae during infection of epithelial cells (abstract no. 224)
12:30-12:40 K. Lidberg (Sweden). Host cell and lactobacilli-derived lactate promote meningococcal proliferation, biofilm formation, and microcolony dispersal rate (abstract no. 294)
12:40-12:50 A. van der Ende (Netherlands). Structure of the meningococcal capsular polysaccharide affects Neisseria meningitidis virulence in a zebrafish embryo infection model (abstract no. 265)
12:50-14:20 Lunch
14:20-15:55 Genomics and Gene Regulation
Chairs: TBC
14:20-14:35 C. Genco (USA). Global gene co-expression network analysis of Neisseria gonorrhoeae and the human host during mucosal infection reveals coordinated interspecies responses (abstract no. 208)
14:35-14:50 M. Chenal (Canada). Discovery of a site-specific single-stranded nuclease (SsnA) involved in the virulence and competence of Neisseria meningitidis (abstract no. 330)
15:05-15:20 M. Kimani (UK). Analysis of associations between phase variation states and meningococcal disease and carriage traits using high throughput phenotypic testing (abstract no. 263)
15:20-15:35 E. Jurga (Canada). Using Metabolic pathway modelling to guide drug discovery in Neisseria gonorrhoeae (abstract no. 178)
15:35-15:45 A. Figueredo (USA). Defining the transcriptional response of Neisseria gonorrhoeae to glucose and L-lactate (abstract no. 107)
15:45-15:55 F. Veyrier (Canada). Evolution of multicellular longitudinally dividing oral cavity symbionts (Neisseriaceae) (abstract no. 55)
15:55-16:25 Coffee break
16:30-18:30 Poster session 1
08:45-10:05 Meningococcal Vaccines and Impact
Chairs: TBC
08:45-09:00 H. Marshall (Australia). 4CMenB vaccine impact on meningococcal B disease, nasopharyngeal carriage of Neisseria meningitidis and gonorrhoea following introduction of an infant and adolescent program in South Australia (abstract no. 199)
09:00-09:15 N. Bhat (USA). Antibody persistence and booster responses four years following infant vaccination with MenAfriVac in healthy Malian children (abstract no. 177)
09:15-09:30 K. Looker (UK). The epidemiological impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study (abstract no. 37)
09:30 -09:45 P. Liberator (USA). Breadth of the human immune response to Trumenba: genotypic and phenotypic characterization of MenB strains that are susceptible in the hSBA (abstract no. 189)
09:45-09:55 C. Rodrigues (UK). Integrating genomic data for public health use: the traffic light system for protein-based meningococcal vaccines (abstract no. 111)
09:55-10:05 H. Marjuki (CDC, USA). Potential cross-protection of serogroup B meningococcal vaccine against meningococcal urethritis (abstract no. 31)
10:05-10:40 Coffee break
10:40-12:35 Epidemiology/Molecular Epidemiology
Chairs: TBC
10:40-11:20 Plenary: Kanny Diallo (Cote d’Ivoire) and Odile Harrison (UK)
11:20-11:35 H. Musah (Ghana). Molecular characteristics and antimicrobial resistance of gonococcal isolates in Northern Ghana (abstract no. 253)
11:35-11:50 L. McNamara (USA). Meningococcal disease in people living with HIV reported through active surveillance in the United States, 2009-2019 (abstract no. 272)
11:50-12:05 M. Osnes (Norway). The sudden emergence of a Neisseria gonorrhoeae outbreak strain, Norway (abstract no. 52)
12:05-12:15 M. Jackson (USA). Does fitness variation explain the population structure of Neisseria meningitidis? (abstract no. 168)
12:15-12:25 L. Leong (Australia). Whole genome sequencing and 4CMenB predicted coverage of N. meningitidis carriage in senior school students in South Australia (abstract no. 126)
12:25-12:35 A. Retchless (USA). Using genomic diversity to inform outbreak strain identification in the USA (abstract no. 97)
12:35-14:20 (Lunch including ’Meet-the-Expert’) 
14:20-15:55 Antibiotic Resistance, Diagnostics and Treatment
Chairs: TBC
14:20-14:35  K. Fernandez (Switzerland). Target product profile for a new generation of in vitro diagnostic tests to identify multiple meningitis pathogens (abstract no. 156)
14:35-14:50 J. Shaughnessy (USA). Development of complement factor H based immunotherapeutic molecules in tobacco plants against multidrug-resistant Neisseria gonorrhoeae (abstract no. 186)
15:05-15:20 O. Ronveaux (Switzerland). Field evaluation of two new meningitis lateral flow rapid diagnostic tests in Niger and Burkina Faso (abstract no. 77)
15:20-15:35 A. van Dam (Netherlands). Emergence and spread of novel Neisseria gonorrhoeae clone MLST7827 with reduced susceptibility to extended-spectrum cephalosporins (abstract no. 151)
15:35-15:45  H. Lavender (UK).  Novel antibody-peptide conjugates against multidrug-resistant N. gonorrhoeae (abstract no. 233)
15:45-15:55 S. Jacobsson (Sweden). Pharmacodynamic evaluation of zoliflodacin dosing, bacterial kill and resistance suppression in Neisseria gonorrhoeae using a dynamic hollow fiber infection model (abstract no. 298)
15:55-16:25 Coffee break
16:45 - 18:45 Poster session 2
07:30 Registration
08:30-10:05 Surface Structures
Chairs: TBC
08:40-09:15  Plenary: Alison Criss (USA)
09:15-09:30 L. Columbus (USA). Structure, dynamics, and function of Opa60 (abstract no. 56)
09:30-09:45 H. Seifert (USA). Mechanisms controlling pilin antigenic variation of the pathogenic Neisseria (abstract no. 281)
09:45-10:00 A. Waltmann (USA). Loss-of-function mutation in MtrCDE does not change the infectivity and fitness of Neisseria gonorrhoeae (abstract no. 187)
10:00-10:35 Coffee break 
10:35-11:55 Physiology and Metabolism
Chairs: TBC
10:35-10:50 G. Binepal (Canada). Revealing a central role for the cylindrical protease, Clp, in meningococcal colonization and disease (abstract no. 236)
10:50-11:05 A. Potter (USA). Dinner date: Metabolic interaction between Neisseria gonorrhoeae and neutrophils (abstract no. 10)
11:05-11:20 J. Dillard (USA). Wisc M YnhG acts as a transpeptidase to create Dap-Dap crosslinks in the gonococcal cell wall (abstract no. 164)
11:20-11:35 A. Sikora (USA). Neisseria gonorrhoeae vaccine candidate Slam2 influences hemoglobin metabolism (abstract no. 93)
11:35-11:45 E. Semchenko (Australia). The multifunctional role of the gonococcal neisserial heparin binding Antigen (NHBA) in virulence (abstract no. 242)
11:45-11:55 T. Ray (USA). Role of the outer membrane transporters TdfH and TdfJ in productive infection of human ectocervical cells by N. gonorrhoeae (abstract no. 73)
12:00-17:00  Afternoon free/social program
07:30 Registration
08:30-09:50 Molecular & Cellular Biology
Chairs: TBC
08:30-08:45 S. Ivanov (USA). Subversion of the host actin cytoskeleton facilitates Neisseria gonorrhoeae colonization and invasion of human macrophages (abstract no. 181)
08:45-09:00 J. Hicks (New Zealand). Can the gonococcus synthesis cysteine? Investigation of sulfurtransferase and cysteine synthesis enzymes as potential therapeutic targets (abstract no. 17)
09:00-09:15 W. Geslewitz (USA). Development and implementation of an inducible Type I-C CRISPR-Interference System in Neisseria gonorrhoeae (abstract no. 284)
09:15-09:30 S. Gray-Owen (Canada). A pathogenic link between Neisseria meningitidis and IgA nephropathy (abstract no. 232)
09:30-09:40 D. Mueller (Germany). Deciphering the role of the CRISPR/Cas system in Neisseria meningitidis in host cell adhesion (abstract no. 166)
09:40-09:50 E. Rodriguez (USA). Role of gonococcal ispD in the meningococcal urethral clade US_NmUC (abstract no. 328)
09:50-10:20 Coffee break
10:20-12:00 Gonococcal Vaccines
Chairs: TBC
10:20-10:50 Plenary: Kate Seib (Australia)
10:50-11:05 E. Islam (Canada). Evaluation of parenterally delivered vaccine adjuvant formulations in mediating mucosal protection against pathogenic Neisseria (abstract no. 238)
11:05-11:20 A. Jerse (USA). The cross-protective efficacy of the serogroup B meningococcal 4CMenB vaccine against experimental gonococcal infection is less pronounced in Chlamydia-infected mice (abstract no. 334)
11:20-11:35 C. MacLennan (UK). GonoVac, a candidate parenteral NOMV gonococcal vaccine that clears gonococci faster than Bexsero in the mouse vaginal infection model (abstract no. 214)
11:35-11:50 P. Massari (USA). Discovery and immune characterization of new N. gonorrhoeae vaccine antigens expressed during natural mucosal infection (abstract no. 115)
11:50-12:00 J. Fegan (Canada). Evaluating vaccine-mediated protection against targets that overcome nutritional immunity in mouse models of gonococcal colonization (abstract no. 211)
12:00-13:30 Lunch including ‘Meet-the-Expert’
13:30-15:05 Antibiotic Resistance, Diagnostics and Treatment
Chairs: TBC
13:30-13:50 S. Meiring (South Africa). Neisseria in South Africa: an update (abstract no. 130)
13:50-14:05 J. Melendez (USA). Molecular epidemiology and phylogeny of high-level azithromycin resistance in Neisseria gonorrhoeae (abstract no. 237)
14:05-14:20 R. Kant (India). In silico Identification of novel drug targets in Neisseria gonorrhoeae by using homology modelling, drug docking studies of a candidate enzyme MurI: Computational approach to combat antimicrobial resistance (abstract no. 3)
14:20-14:35 S. Palace (USA). RNA polymerase mutations cause cephalosporin resistance in clinical Neisseria gonorrhoeae isolates (abstract no. 124)
14:35-14:45 A. Maina (Kenya). Symptomatic approach to Neisseria gonorrhoeae management performs better in men than women: a cross-sectional study in Nairobi, Kenya (abstract no. 60)
14:45-14:55 A. Iradukundo Mahoro (Rwanda). Antimicrobial susceptibility pattern of Neisseria gonorrhoeae isolated from male patients attending Biryogo Health Centre in Kigali, Rwanda (abstract no. 249)
14:55-15:05 S. Peters (Germany). Click-Correlative light electron microscopy for imaging and tracking of functionalized antibacterial sphingolipids in Neisseria meningitidis (abstract no. 63)
15:05-15:30 Coffee break
15:30-17:00  Meningococcal Vaccines and Impact
Chairs: TBC
15:30-15:45 F. Bidmos (UK). Reverse Vaccinology 2.0 approach to meningococcal vaccine antigen discovery (abstract no. 171)
15:45-16:00 I. Delany (Italy). Interrogation of Human monoclonal antibodies induced by Bexsero to identify protective antigens contained in the OMV component (abstract no. 204)
16:00-16:15 J. Carr (UK). Impact of the UK quadrivalent MenACWY vaccination programme on oropharyngeal carriage of meningococci in adolescents aged 16-19 years (abstract no. 203)
16:15-16:30 O. Sall (Sweden). Predicted strain coverage for Bexsero and Trumenba vaccines among invasive meningococcal isolates in Sweden, 2014-2018 (abstract no. 5)
16:30-16:40 E. Currie (Canada). Protection against Neisseria meningitidis nasal colonization is mediated by antibody dependent opsonophagocytosis (abstract no. 215)
16:40-16:50 S. Ladhani (UK). The Impact of the meningococcal B vaccine, 4CMenB, on group W disease in England (abstract no. 134)
16:50-17:00 M. Ohm (Netherlands). Protection against invasive meningococcal disease and vaccination policy in the Netherlands (abstract no. 299)
18:30 - late Gala dinner
07:30 Registration
09:00-10:35 Antibiotic Resistance, Diagnostics and Treatment
Chairs: TBC
09:00-09:30 Plenary: Rob Nicholas (USA)
09:30-09:45 R. Howie (USA). Antimicrobial resistance in N. meningitidis serogroup Y— United States, 2019-present (abstract no. 266)
09:45-10:00 S. Ram (USA). DNA-encoded anti-lipooligosaccharide monoclonal antibody engineered to enhance complement activation as a vaccination strategy against gonorrhoea (abstract no. 145)
10:00-10:15 A. Le Van (USA). The in vivo fitness defect conferred by a commonly isolated fluoroquinolone resistance-conferring parC mutation is restored by the selection of compensatory mutations during experimental murine infection (abstract no. 322)
10:15-10:25 M. Chen (China). Decreased susceptibility of meningococcus to penicillin in Shanghai, China during 1965 and 2019 (abstract no. 15)
10:25-10:35 S. Clark (UK). An investigation into rifampicin hetero-resistance among invasive meningococci in the UK (abstract no. 132)
10:35-11:05 Coffee break
11:05-12:10 Host Defence 
Chairs: TBC
11:05-11:20 S. Dhital (Australia). Role of Neisseria gonorrhoeae secreted outer membrane vesicles (OMVs) in immune modulation (abstract no. 197)
11:20-11:35 L. Werner (USA). Human serum suppression of neutrophil anti-gonococcal activity (abstract no. 9)
11:35-11:50 S. Xu (Canada). Decidualization of the endometrium as sequelae caused by gonorrhea-induced uterine inflammation (abstract no. 89)
11:50-12:00 D. Golenbock (USA). USA estrogen-induced interferon-epsilon expressed in the female genital tract allows N. gonorrhoeae to evade innate immune clearance (abstract no. 327)
12:00-12:10 A. Dale (UK). The commensal Neisseria lactamica induces cross-reactive human B cell responses against the pathogen Neisseria meningitidis (abstract no. 148)
12:10-12:25 Closing and announcement of next meeting (IPNC 2023)


After careful consideration, and a keen interest for an in-person meeting in South Africa, it is with regret that we are forced to postpone this meeting yet again. Current COVID-19 regulations in South Africa regarding mass gatherings prohibit the hosting of an in-person meeting at this time.

  • New dates for IPNC South Africa are 9-14 October 2022.
  • Abstracts may remain in the system or be withdrawn.
  • Please communicate with Scatterlings regarding hotel booking refunds or rollover of bookings to 2022, or if you have any other queries.
  • The Boston IPNC meeting will proceed as planned (from 23-30 September 2023 at the Boston Park Plaza, Massachusetts, USA).
  • We will work together with Boston to plan a complementary scientific program for both meetings.
  • We apologise for any inconvenience – please bear with us as we navigate through these uncertain times.